Advertising

AbbVie Inc.

ABBV-N

NYSE:ABBV

118.19
0.65 (0.55%)
AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs. It originated in 2013 as a spin-off of Abbott Laboratories.
More at Wikipedia

Analysis and Opinions about ABBV-N

Signal
Opinion
Expert
Chart
COMMENT
COMMENT
June 28, 2021
https://finance.yahoo.com/news/abbvies-abbv-rinvoq-snda-decision-114811600.html AbbVie announced that the FDA won't grant a decision on the application of AbbVie's arthritis drug, Rinvoq (though it has been approved in Europe). He's very disappointment that AbbVie has not gotten the FDA vote through. If Runvoq does not pass, it could be very bad for Abbvie. He is very concerned.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
June 28, 2021
https://finance.yahoo.com/news/abbvies-abbv-rinvoq-snda-decision-114811600.html AbbVie announced that the FDA won't grant a decision on the application of AbbVie's arthritis drug, Rinvoq (though it has been approved in Europe). He's very disappointment that AbbVie has not gotten the FDA vote through. If Runvoq does not pass, it could be very bad for Abbvie. He is very concerned.
BUY
BUY
June 15, 2021

Trades at 10x earnings. Fine fundamentals. Owns Humera, a hugely profitable drug. ABBV bought Allergan to dilute the dependence on Humera revenues. That's when he bought ABBV, because the company became less risky. A fine 4.5% dividend. Caveat: in 2023, Humera goes off-patent, so ABBV has been busy replacing these future lost revenues (so they bought Allergan). They also have been developing and acquiring new drugs. Worries of going off-patent are already built in share prices, so the worry is in the past.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
June 15, 2021

Trades at 10x earnings. Fine fundamentals. Owns Humera, a hugely profitable drug. ABBV bought Allergan to dilute the dependence on Humera revenues. That's when he bought ABBV, because the company became less risky. A fine 4.5% dividend. Caveat: in 2023, Humera goes off-patent, so ABBV has been busy replacing these future lost revenues (so they bought Allergan). They also have been developing and acquiring new drugs. Worries of going off-patent are already built in share prices, so the worry is in the past.

Gordon Reid
Price
$115.745
Owned
Yes
BUY
BUY
May 25, 2021

A great holding. Pays nearly a 5% dividend yield. They bought Allergan some years ago. Humera used to be a big chunk of company revenues, but is now lower and more comfortable. Cash flow is strong. Earnings valuation is attraction. Caveat: humera goes off patent in 2023, so this will impact Abbvie's revenue stream. However, ABBV is smart by lowering the impact of humera by developing other drugs that bring in $1 billion revenues. The humera factor is fully discounted in the current Abbvie price. So, he would absolutely buy ABBV. You're now buying it at a 20% discount if ABBV didn't have that patent-expiration overhang.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
May 25, 2021

A great holding. Pays nearly a 5% dividend yield. They bought Allergan some years ago. Humera used to be a big chunk of company revenues, but is now lower and more comfortable. Cash flow is strong. Earnings valuation is attraction. Caveat: humera goes off patent in 2023, so this will impact Abbvie's revenue stream. However, ABBV is smart by lowering the impact of humera by developing other drugs that bring in $1 billion revenues. The humera factor is fully discounted in the current Abbvie price. So, he would absolutely buy ABBV. You're now buying it at a 20% discount if ABBV didn't have that patent-expiration overhang.

Gordon Reid
Price
$114.530
Owned
Yes
BUY
BUY
May 14, 2021

There are some fears of loosing patent protection with Humera, but patients seem to be want to stick with the brand name. When they acquired Allergan, they got the botox franchise, which is a reopening play. 4.5% yield. A good long term play. They have a good pipeline as well.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
May 14, 2021

There are some fears of loosing patent protection with Humera, but patients seem to be want to stick with the brand name. When they acquired Allergan, they got the botox franchise, which is a reopening play. 4.5% yield. A good long term play. They have a good pipeline as well.

JoAnne Feeney
Price
$116.910
Owned
Yes
TOP PICK
TOP PICK
April 27, 2021
Stockchase Research Editor: Michael O'Reilly ABBV is one of the highest quality pharma stocks you can own with a $194 billion market cap and is a good defensive holding paying an excellent dividend (backed by a payout ratio of 50% of cash flow). Best known for its Crohn's disease treatment Humira, which provided over $19 billion in revenue last year. We would buy this with a stop loss at $90, looking to achieve $125 -- upside potential over 11%. Not a growth stock, but a good dividend payer. Yield 4.45% (Analysts’ price target is $122.17)
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 27, 2021
Stockchase Research Editor: Michael O'Reilly ABBV is one of the highest quality pharma stocks you can own with a $194 billion market cap and is a good defensive holding paying an excellent dividend (backed by a payout ratio of 50% of cash flow). Best known for its Crohn's disease treatment Humira, which provided over $19 billion in revenue last year. We would buy this with a stop loss at $90, looking to achieve $125 -- upside potential over 11%. Not a growth stock, but a good dividend payer. Yield 4.45% (Analysts’ price target is $122.17)
PAST TOP PICK
PAST TOP PICK
April 13, 2021

(A Top Pick May 12/20, Up 24%) He's sticking with it. There's more upside to come. Their biggest product was Humera, a massive drug. A few years ago, they bought Allergan and their Botox drug, which reduced company dependence on Humera for company revenues. ABBV has some new drugs in the pipeline that are reaching $1 billion in sales, so this further spreads the risk away from Humera. It trades at a cheap 9x PE and pays a 5% dividend. Warning: in 2023, Humera goes off patent and that will mean a challenge for ABBV to replace that revenue stream (Humera makes up 32% of all revenues, though it used to be 65% before Botox).

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
April 13, 2021

(A Top Pick May 12/20, Up 24%) He's sticking with it. There's more upside to come. Their biggest product was Humera, a massive drug. A few years ago, they bought Allergan and their Botox drug, which reduced company dependence on Humera for company revenues. ABBV has some new drugs in the pipeline that are reaching $1 billion in sales, so this further spreads the risk away from Humera. It trades at a cheap 9x PE and pays a 5% dividend. Warning: in 2023, Humera goes off patent and that will mean a challenge for ABBV to replace that revenue stream (Humera makes up 32% of all revenues, though it used to be 65% before Botox).

Gordon Reid
Price
$107.970
Owned
Yes
BUY WEAKNESS
BUY WEAKNESS
March 17, 2021
There was an issue with a key drug of theirs today (the FDA delayed reviewing it for 3 months). He suspects this is just a speed bump, expects a downgrade or two tomorrow, but this is a buying opportunity.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
March 17, 2021
There was an issue with a key drug of theirs today (the FDA delayed reviewing it for 3 months). He suspects this is just a speed bump, expects a downgrade or two tomorrow, but this is a buying opportunity.
Jim Cramer - Mad Money
Price
$105.040
Owned
Unknown
BUY
BUY
February 12, 2021
It beat earnings, but has struggled the past week. It stalled because people can't get their Botox (a big part of their business) during the lockdown, but ABBV's migraine franchise is fine and the drugs replacing Humera, their big product, are working. Also, this is cheap at 8x earnings and it pays a 5% yield. A bargain now.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 12, 2021
It beat earnings, but has struggled the past week. It stalled because people can't get their Botox (a big part of their business) during the lockdown, but ABBV's migraine franchise is fine and the drugs replacing Humera, their big product, are working. Also, this is cheap at 8x earnings and it pays a 5% yield. A bargain now.
Jim Cramer - Mad Money
Price
$104.440
Owned
Unknown
TOP PICK
TOP PICK
February 11, 2021

Large cap biotech. Humera generates $20B a year in revenue. Exceptional job at using that cashflow to diversify, as in buying Allergan. 15% EPS, clean balance sheet. Its value will eventually be realized. Yield is 5%. (Analysts’ price target is $121.05)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
February 11, 2021

Large cap biotech. Humera generates $20B a year in revenue. Exceptional job at using that cashflow to diversify, as in buying Allergan. 15% EPS, clean balance sheet. Its value will eventually be realized. Yield is 5%. (Analysts’ price target is $121.05)

Paul MacDonald
Price
$103.650
Owned
Yes
BUY
BUY
December 16, 2020

All big pharmas have been treading water. Patent legislation left them with a leaky boat. He's gravitated toward the bio-pharmas. His favourite in that space is AbbVie, as it's good on fundamentals and financials, inexpensive, very fine dividend, great cashflow generator.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
December 16, 2020

All big pharmas have been treading water. Patent legislation left them with a leaky boat. He's gravitated toward the bio-pharmas. His favourite in that space is AbbVie, as it's good on fundamentals and financials, inexpensive, very fine dividend, great cashflow generator.

Gordon Reid
Price
$104.280
Owned
Yes
COMMENT
COMMENT
December 11, 2020
This discuss their immunology franchise on Monday. If they can present good numbers on new drugs to replace Humera--their biggest-selling drug, but is losing patent protection soon--this will take pressure off this drug and this stock will climb futher. ABBV has a lot of growth and pays a good yield.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
December 11, 2020
This discuss their immunology franchise on Monday. If they can present good numbers on new drugs to replace Humera--their biggest-selling drug, but is losing patent protection soon--this will take pressure off this drug and this stock will climb futher. ABBV has a lot of growth and pays a good yield.
Jim Cramer - Mad Money
Price
$106.340
Owned
Unknown
BUY
BUY
November 19, 2020
You would own it for the strong yield at 5.25%. Valuation is quite cheap relative to peers. Good earnings growth and dividend growth. They raised their guidance which is positive. The split congress helps this name since pushing drug prices down will be harder.
Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
November 19, 2020
You would own it for the strong yield at 5.25%. Valuation is quite cheap relative to peers. Good earnings growth and dividend growth. They raised their guidance which is positive. The split congress helps this name since pushing drug prices down will be harder.
Stan Wong
Price
$99.450
Owned
Yes
BUY
BUY
October 23, 2020

Likes it. A spin-off of Abbott Labs. They have made a purchase of Allergan that diluted the concentration of Humira. The company will get its legs so buy it and be patient.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
October 23, 2020

Likes it. A spin-off of Abbott Labs. They have made a purchase of Allergan that diluted the concentration of Humira. The company will get its legs so buy it and be patient.

Gordon Reid
Price
$84.340
Owned
Yes
TOP PICK
TOP PICK
October 20, 2020

A sort of contrarian call. Humera is their primary drug (US$19.5 billion annually) used for various immunology disorders. Competitors will nip at their heels here, of course, given that success. They have this drug through 2023. As importantly, they bought Allergan, makers of botox, which is executing. Pays a .5.5% dividend and trades at 7x earnings. There's a disconnect between company value/performance and market perception. A great balance sheet to support the dividend. (Analysts’ price target is $110.26)

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
October 20, 2020

A sort of contrarian call. Humera is their primary drug (US$19.5 billion annually) used for various immunology disorders. Competitors will nip at their heels here, of course, given that success. They have this drug through 2023. As importantly, they bought Allergan, makers of botox, which is executing. Pays a .5.5% dividend and trades at 7x earnings. There's a disconnect between company value/performance and market perception. A great balance sheet to support the dividend. (Analysts’ price target is $110.26)

Paul MacDonald
Price
$84.760
Owned
Yes
DON'T BUY
DON'T BUY
October 14, 2020

Owns Abbott Labs instead, as it's more diversified. ABBV is pure pharma. They need to broaden reliance on a few key drugs.

Show full opinionHide full opinion
AbbVie Inc. (ABBV-N)
October 14, 2020

Owns Abbott Labs instead, as it's more diversified. ABBV is pure pharma. They need to broaden reliance on a few key drugs.

Showing 1 to 15 of 79 entries

AbbVie Inc.(ABBV-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 14

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 15

Stockchase rating for AbbVie Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

AbbVie Inc.(ABBV-N) Frequently Asked Questions

What is AbbVie Inc. stock symbol?

AbbVie Inc. is a American stock, trading under the symbol ABBV-N on the New York Stock Exchange (ABBV). It is usually referred to as NYSE:ABBV or ABBV-N

Is AbbVie Inc. a buy or a sell?

In the last year, 15 stock analysts published opinions about ABBV-N. 14 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for AbbVie Inc..

Is AbbVie Inc. a good investment or a top pick?

AbbVie Inc. was recommended as a Top Pick by Jim Cramer - Mad Money on 2021-06-28. Read the latest stock experts ratings for AbbVie Inc..

Why is AbbVie Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is AbbVie Inc. worth watching?

15 stock analysts on Stockchase covered AbbVie Inc. In the last year. It is a trending stock that is worth watching.

What is AbbVie Inc. stock price?

On 2021-07-23, AbbVie Inc. (ABBV-N) stock closed at a price of $118.19.